Prof. Dr. Matthias Ebert, MD

Professor of Gastroenterology at the University of Heidelberg and Director of the Department of Medicine II of the University Hospital Mannheim. His group focuses on translational gastrointestinal cancer research with a strong clinical background in clinical trials and translational studies, including patient-derived models.

Prof. Ebert is a member of the Executive Board of the German Gastroenterology Society (DGVS), and of the Executive Board of Medical Oncology Group (AIO) of the German Cancer Society; He published more than 300 peer reviewed publications and 7 patents in the area of molecular diagnostics; He is currently active in the DFG funded graduate school on innate immunity in cancer and tissue damage (GRK2727) and leads one of the largest living biobanks with patient-derived organoids in Europe.

Prof. Ebert is lead investigator of currently more than 25 clinical trials, including IITs in immune oncology treatment protocols, and several phase I and II trials, with protocols for all areas of gastrointestinal cancers and chronic inflammatory conditions. Prof. Ebert, in cooperation with Biotech companies in Europe and US, has filed/been awarded multiple patents and has acted as consultant for a wide variety of industrial parties within the biomedical and pharmaceutical sphere.

Prof. Ebert acts as Clinical Director of the Mannheim School of Translational Medicine und is responsible for the DFG-funded Clinician-Scientist-Programme „ICON: Interfaces and Interventions in Chronic Conditions“ at Mannheim Medical Faculty of Heidelberg University.